TET1-TRPV4 Signaling Contributes to Bone Cancer Pain in Rats

Area of Science:

• Neuroscience
• Oncology
• Epigenetics

Background:

• Bone cancer pain (BCP) presents significant challenges due to unclear pathogenesis and limited treatment options.
• Peripheral sensitization of dorsal root ganglion (DRG) neurons is a key mechanism in BCP.
• Epigenetic modifications are increasingly recognized as crucial in chronic pain development.

Purpose of the Study:

• To investigate the role of DNA hydroxymethylase ten-eleven translocation 1 (TET1) in BCP.
• To explore the involvement of the ion channel TRPV4 in BCP.
• To determine the relationship between TET1 and TRPV4 in the context of BCP.

Main Methods:

• Assessed TET1 and TET2 expression in the DRG of BCP rats.
• Utilized intrathecal injections of a TET1 inhibitor (Bobcat339) to evaluate its effect on hyperalgesia.
• Measured TRPV4 expression in the DRG of BCP rats.
• Administered a TRPV4 inhibitor (HC067047) to assess its impact on hyperalgesia.

Main Results:

• TET1 expression was significantly upregulated in the DRG of BCP rats, while TET2 expression remained unchanged.
• Inhibition of TET1 effectively alleviated mechanical hyperalgesia in BCP rats.
• TRPV4 expression was significantly elevated in the DRG of BCP rats.
• Inhibition of TRPV4 also significantly attenuated mechanical hyperalgesia.
• TET1 inhibition led to a downregulation of TRPV4 expression.

Conclusions:

• TET1 plays a significant role in BCP, potentially by upregulating TRPV4 expression in DRG neurons.
• TRPV4 is implicated in the peripheral sensitization contributing to BCP.
• TET1 and TRPV4 represent potential therapeutic targets for managing bone cancer pain.